BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
70.24
+0.55 (0.79%)
At close: Jun 26, 2026, 4:00 PM EDT
70.91
+0.67 (0.95%)
After-hours: Jun 26, 2026, 7:59 PM EDT
BridgeBio Pharma Employees
As of December 31, 2025, BridgeBio Pharma had 839 total employees, including 834 full-time and 5 part-time employees. The number of employees increased by 109 or 14.93% compared to the previous year.
Employees
839
Change (1Y)
109
Growth (1Y)
14.93%
Revenue / Employee
$691,249
Profits / Employee
-$860,014
Market Cap
13.76B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
BBIO News
- 3 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - BridgeBio Pharma Transcript: AGM 2026 - Transcripts
- 5 days ago - BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026 - GlobeNewsWire
- 22 days ago - BridgeBio Pharma Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 24 days ago - BridgeBio Pharma Slides: Corporate presentation - Filings
- 4 weeks ago - BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 - GlobeNewsWire
- 6 weeks ago - BridgeBio Pharma Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 - GlobeNewsWire